Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
In the latest session, Xenon Pharmaceuticals Inc (NASDAQ: XENE) closed at $41.9 up 3.28% from its previous closing price of $40.57. In other words, the price has increased by $3.28 from its previous closing price. On the day, 0.51 million shares were traded. XENE stock price reached its highest trading level at $42.185 during the session, while it also had its lowest trading level at $40.66.
Ratios:
For a deeper understanding of Xenon Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.14 and its Current Ratio is at 15.14. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
On May 07, 2025, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $55.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $67.Deutsche Bank initiated its Buy rating on February 11, 2025, with a $67 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 01 ’25 when MORTIMER IAN sold 25,000 shares for $40.16 per share. The transaction valued at 1,004,000 led to the insider holds 31,302 shares of the business.
IAN MORTIMER bought 25,000 shares of XENE for $1,004,117 on Oct 01 ’25. On Sep 19 ’25, another insider, SHERRY AULIN, who serves as the Former officer of the company, bought 2,548 shares for $37.08 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XENE now has a Market Capitalization of 3230733056 and an Enterprise Value of 2751902976. For the stock, the TTM Price-to-Sale (P/S) ratio is 430.76 while its Price-to-Book (P/B) ratio in mrq is 5.09. Its current Enterprise Value per Revenue stands at 366.92 whereas that against EBITDA is -8.722.
Stock Price History:
The Beta on a monthly basis for XENE is 1.11, which has changed by -0.06326485 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, XENE has reached a high of $46.00, while it has fallen to a 52-week low of $26.74. The 50-Day Moving Average of the stock is 10.40%, while the 200-Day Moving Average is calculated to be 17.85%.
Shares Statistics:
For the past three months, XENE has traded an average of 835.75K shares per day and 794220 over the past ten days. A total of 76.94M shares are outstanding, with a floating share count of 74.02M. Insiders hold about 4.00% of the company’s shares, while institutions hold 103.85% stake in the company. Shares short for XENE as of 1759190400 were 7705812 with a Short Ratio of 9.22, compared to 1756425600 on 6908299. Therefore, it implies a Short% of Shares Outstanding of 7705812 and a Short% of Float of 11.14.
Earnings Estimates
The market rating for Xenon Pharmaceuticals Inc (XENE) is a result of the insights provided by 13.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$1.23, with high estimates of -$0.97 and low estimates of -$1.55.
Analysts are recommending an EPS of between -$3.85 and -$4.72 for the fiscal current year, implying an average EPS of -$4.29. EPS for the following year is -$4.59, with 15.0 analysts recommending between -$2.15 and -$5.4.
